Literature DB >> 22981290

The impact of a vaccination campaign against hepatitis B on the further decrease of hepatitis B virus infection in a southern Italian town over 14 years.

Tommaso Stroffolini1, Vincenzo Guadagnino, Maria Rapicetta, Francesca Menniti Ippolito, Benedetto Caroleo, Giovambattista De Sarro, Alfredo Focà, Maria Carla Liberto, Aida Giancotti, Giorgio S Barreca, Nadia Marascio, Flavia Lombardo, Orietta Staltari.   

Abstract

BACKGROUND: Hepatitis B virus infection has decreased in Italy. The aims of this study were to identify changes, if any, in the epidemiological pattern of HBV infection in a southern Italian town first surveyed in 1996 and to assess the effectiveness of vaccination campaign against hepatitis B.
METHODS: In 2010, subjects were selected from the census by a systematic 1:4 random sampling procedure. Hepatitis B surface antigen (HBsAg) and antibodies to hepatitis B core antigen (anti-HBc) were detected by ELISA. Associations (odds ratios) linking exposure to hepatitis B virus infection to potential risk factors were estimated by univariate and multivariate analyses.
RESULTS: Of the 1100 eligible subjects, 1020 (92.0%) agreed to participate. The prevalences of HBsAg (0.6%) and anti-HBc (15.2%) were significantly lower than in 1996 (0.8% and 21.5%) (p<0.01). No subject below 30 years of age (those that had been targeted for compulsory immunization) had been exposed to HBV infection. At multiple logistic regression analysis, age>45 years (OR=9.8; 95% CI=5.1-18.7) and past use of glass syringes (OR=1.9; 95% CI=1.2-3.1) independently predicted the likelihood of anti-HBc positivity.
CONCLUSIONS: These results, albeit obtained in a small town and thus not generalizable, confirm the continuous decreasing trend of HBV infection and demonstrate the effectiveness of the Italian hepatitis B vaccination program.
Copyright © 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22981290     DOI: 10.1016/j.ejim.2012.08.009

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  6 in total

1.  Hepatitis delta infection in Italian patients: towards the end of the story?

Authors:  Tommaso Stroffolini; Evangelista Sagnelli; Caterina Sagnelli; Maurizio Russello; Massimo De Luca; Floriano Rosina; Bruno Cacopardo; Giuseppina Brancaccio; Caterina Furlan; Giovanni Battista Gaeta; Anna Licata; Piero Luigi Almasio
Journal:  Infection       Date:  2016-11-05       Impact factor: 3.553

2.  Clinical, epidemiological and virological features of acute hepatitis B in Italy.

Authors:  Ornella Zuccaro; Luisa Romanò; Alfonso Mele; Andrea Mariano; Massimo Clementi; Maria Elena Tosti; Gloria Taliani; Claudio Galli; Alessandro Remo Zanetti; Enea Spada
Journal:  Infection       Date:  2015-02-20       Impact factor: 3.553

3.  Prevalence and factors associated with hepatitis B virus infection among household members: a cross-sectional study in Beijing.

Authors:  Xuan Zhao; Xuefeng Shi; Min Lv; Beibei Yuan; Jiang Wu
Journal:  Hum Vaccin Immunother       Date:  2021-02-19       Impact factor: 3.452

4.  Effectiveness of Hepatitis B Vaccination Campaign in Italy: Towards the Control of HBV Infection for the First Time in a European Country.

Authors:  Tommaso Stroffolini; Filomena Morisco; Luigina Ferrigno; Giuseppina Pontillo; Giuseppina Iantosca; Valentina Cossiga; Simonetta Crateri; Maria Elena Tosti
Journal:  Viruses       Date:  2022-01-26       Impact factor: 5.048

Review 5.  Insights into induction of the immune response by the hepatitis B vaccine.

Authors:  Federico Alejandro Di Lello; Alfredo Pedro Martínez; Diego Martín Flichman
Journal:  World J Gastroenterol       Date:  2022-08-21       Impact factor: 5.374

6.  Hepatitis B vaccination coverage among healthcare workers at national hospital in Tanzania: how much, who and why?

Authors:  Dotto Aaron; Tumaini J Nagu; John Rwegasha; Ewaldo Komba
Journal:  BMC Infect Dis       Date:  2017-12-20       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.